TD Cowen on Mirum Pharmaceuticals (MIRM): 'Remain at Buy for base business and pipeline'
Tweet Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating and $95.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
